Status: Recommended | ||
Ravulizumab (Ultomiris®) is recommended as an option for use within NHS Wales for the treatment of paroxysmal nocturnal haemoglobinuria in paediatric patients with a body weight of 10 kg or above:
This recommendation applies only in circumstances where the approved Patient Access Scheme (PAS) is utilised or where the list/contract price is equivalent or lower than the PAS price. |
||
|
||
Medicine details |
||
Medicine name | ravulizumab (Ultomiris®) | |
Formulation | 300 mg/3 mL concentrate for solution for infusion and 1,100 mg/11 mL concentrate for solution for infusion | |
Reference number | 4869 | |
Indication | For the treatment of paediatric patients with a body weight of 10 kg or above with paroxysmal nocturnal haemoglobinuria (PNH):
|
|
Company | Alexion Pharma UK Ltd | |
BNF chapter | Nutrition & blood | |
Submission type | Licence extension for paediatric use | |
Status | Recommended | |
Advice number | 0322 | |
AWMSG meeting date | 09/02/2022 | |
Date of issue | 23/02/2022 | |
Commercial arrangement | PAS | |
Further information See NICE guidance for ravulizumab (Ultomiris® ) for the treatment of paroxysmal nocturnal haemoglobinuria in adults (TA698, originally published May 2021). |